Hepatic Involvement across the Metabolic Syndrome Spectrum: Non-Invasive Assessment and Risk Prediction Using Machine Learning.

Metabolic-dysfunction-associated steatotic liver disease (MASLD) and metabolic syndrome (MetS) are inextricably linked conditions, both of which are experiencing an upward trend in prevalence, thereby exerting a substantial clinical and economic burden. The presence of MetS should prompt the search for metabolic-associated liver disease. Liver fibrosis is the main predictor of liver-related morbidity and mortality.

Effects of simvastatin in patients with viral chronic hepatitis C.

Background/aims: A geranyl-geranylated protein is synthesized during chronic hepatitis C virus replication; statins can inhibit this synthesis. We aimed at studying the effects of administrating simvastatin to patients who finished the standard antiviral therapy and who did not have hepatic cytolysis.

Methodology: A total of 101 patients were divided into 3 groups.